

# Pieter van Baal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2352905/publications.pdf>

Version: 2024-02-01

31  
papers

531  
citations

686830

13  
h-index

676716

22  
g-index

32  
all docs

32  
docs citations

32  
times ranked

707  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. <i>Pharmacoeconomics</i> , 2022, 40, 233-239.	1.7	4
2	Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands. <i>Value in Health</i> , 2022, 25, 731-735.	0.1	12
3	Distributional consequences of including survivor costs in economic evaluations. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2606-2613.	0.8	3
4	The economics of improving global infectious disease surveillance. <i>BMJ Global Health</i> , 2021, 6, e006597.	2.0	11
5	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. <i>Social Science and Medicine</i> , 2021, 289, 114414.	1.8	3
6	Improving maternal and child health in Pakistan: a programme evaluation using a difference in difference analysis. <i>BMJ Global Health</i> , 2021, 6, e006453.	2.0	3
7	Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. <i>Value in Health</i> , 2020, 23, 1027-1033.	0.1	10
8	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. <i>European Journal of Health Economics</i> , 2020, 21, 1329-1350.	1.4	3
9	Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0. <i>Value in Health</i> , 2020, 23, 1453-1461.	0.1	11
10	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 13.	0.6	11
11	Prospective impact of tobacco eradication and overweight and obesity eradication on future morbidity and health-adjusted life expectancy: simulation study. <i>Journal of Epidemiology and Community Health</i> , 2020, 74, 354-361.	2.0	7
12	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. <i>European Journal of Health Economics</i> , 2019, 20, 175-180.	1.4	73
13	A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. <i>Health Economics (United Kingdom)</i> , 2019, 28, 87-100.	0.8	39
14	Future unrelated medical costs need to be considered in cost effectiveness analysis. <i>European Journal of Health Economics</i> , 2019, 20, 1-5.	1.4	25
15	Health care input constraints and cost effectiveness analysis decision rules. <i>Social Science and Medicine</i> , 2018, 200, 59-64.	1.8	26
16	Should cost effectiveness analyses for NICE always consider future unrelated medical costs?. <i>BMJ: British Medical Journal</i> , 2017, 359, j5096.	2.4	14
17	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-effectiveness Analysis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 237-248.	0.8	41
18	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1005-1019.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Forecasting differences in life expectancy by education. <i>Population Studies</i> , 2016, 70, 201-216.	1.1	20
20	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. <i>Health Economics (United Kingdom)</i> , 2016, 25, 933-938.	0.8	23
21	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. <i>European Journal of Public Health</i> , 2015, 25, 791-795.	0.1	14
22	Trends in Dutch hospital spending by age and disease 1994-2010. <i>Health Policy</i> , 2015, 119, 316-323.	1.4	6
23	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.. <i>Pharmacoeconomics</i> , 2013, 31, 369-373.	1.7	12
24	Important cost categories not included: transcatheter aortic valve implantation probably less cost-effective. <i>Heart</i> , 2012, 98, 1182.1-1182.	1.2	0
25	DYNAMO-HIA - A Dynamic Modeling Tool for Generic Health Impact Assessments. <i>PLoS ONE</i> , 2012, 7, e33317.	1.1	51
26	PAID 1.0 in Practice. <i>Pharmacoeconomics</i> , 2011, 29, 545-547.	1.7	1
27	Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. <i>Population Health Metrics</i> , 2011, 9, 17.	1.3	39
28	LONG-TERM EFFECTS OF ALCOHOL POLICIES: AN ECONOMIC PERSPECTIVE. <i>Addiction</i> , 2010, 105, 395-397.	1.7	1
29	The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. <i>Preventive Medicine</i> , 2008, 46, 127-132.	1.6	28
30	Realistic Spatial Backcloth is not that Important in Agent Based Simulation Research. , 2008, , 19-34.		13
31	Economics and public health: engaged to be happily married!. <i>European Journal of Public Health</i> , 2007, 17, 122-123.	0.1	15